An Efficacy and Safety Study of Ravulizumab in ALS Participants
Clinical trial NCT04248465 · TERMINATED
Trial details
- NCT number
- NCT04248465
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-30
- Primary completion
- 2021-10-17
- Enrollment
- 382
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.